BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...medulloblastoma. University of Texas Health Science Center at San Antonio Proteasome subunit beta 9 (PSMB9; LMP2...
BioCentury | Jan 13, 2018
Finance

JPM jolt

...targeting Epstein-Barr virus nuclear antigen 1 (EBNA1), Epstein-Barr virus latent membrane protein 1 (LMP1) and LMP2...
BioCentury | Dec 1, 2017
Clinical News

QIMR reports updated Phase I data for MS candidate

...targeting Epstein-Barr virus nuclear antigen 1 (EBNA1), Epstein-Barr virus latent membrane protein 1 (LMP1) and LMP2...
...latent membrane protein 1 (LMP1) Description: Autologous Epstein-Barr virus-specific T cells targeting EBNA1, LMP1 and LMP2...
...Milestone: NA Allison Johnson Autologous ATA190 Atara Biotherapeutics Inc. QIMR Berghofer Medical Research Institute Epstein-Barr virus latent membrane protein 1 (LMP1) Epstein-Barr virus latent membrane protein 2 (LMP2) Americas...
BioCentury | Sep 23, 2017
Emerging Company Profile

Selective suppression

Kezar Life Sciences Inc. is targeting the immunoproteasome to selectively suppress the hyperactive immune cells that drive autoimmunity. The company expects its biologics to have the rapid onset and broad activity of steroids, but without...
BioCentury | Apr 11, 2017
Distillery Techniques

Disease models

...TECHNOLOGY: Animal models LMP1 / LMP2 -overexpressing mice depleted of T cells and NKT cells could...
...therapies for EBV-positive lymphoproliferative disease. Mice with germinal center B cell-specific overexpression of LMP1 and LMP2...
...include using the model to screen for therapies. DESCRIPTION: Epstein-Barr virus latent membrane protein 1 (LMP1)/LMP2-overexpressing...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Transplant

INDICATION: Graft rejection; heart transplant rejection Mouse studies identified a dipeptide inhibitor of PSMB8 that could help prevent skin and heart transplant rejection. Chemical synthesis and testing in in vitro activity assays of dipeptides yielded...
BioCentury | Mar 31, 2014
Clinical News

MVA-EBNA/LMP2 vaccine: Phase Ib started

...DDO ) began a U.K. Phase Ib trial to evaluate 3 doses of intradermal MVA-EBNA/LMP2...
...also in a Hong Kong Phase II trial. Cancer Research UK , London, U.K. Product: MVA-EBNA/LMP2...
BioCentury | Mar 1, 2012
Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Mouse model of Epstein-Barr virus (EBV)-driven B cell lymphoma Mice that express EBV latent membrane protein 1 (Lmp-1) in B cells could aid the development...
BioCentury | Apr 21, 2011
Strategy

A conversation with Gregory Verdine

What will drugs look like in the coming decade? This is the question being posed by Gregory Verdine and the next-generation therapeutic modalities team he leads at Third Rock Ventures . One answer, Verdine believes, is...
BioCentury | Oct 12, 2009
Emerging Company Profile

BerGenBio: Controlling Interference

Conventional RNAi methods can neither control nor vary the extent to which a protein's expression is blocked, and so provide only rough insights into target function at one level of inhibition. BerGenBio A/S says its...
Items per page:
1 - 10 of 14